Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Adicet Bio Q3 2026 Results: Net Loss of $18.9M, Loss Narrows

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, with its lead candidate prula-cel (ADI-001) currently in Phase 1 trials. The company reported 9,361,596 shares of common stock outstanding as of November 3, 2026, and highlighted significant risks including the need for substantial additional financing and reliance on third-party manufacturing.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-18.9-26.9
Net income-18.9-26.9
EPS (diluted, $ a share)$-1.76$-4.72

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ACET. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Adicet Bio, Inc.: key numbers

Share price
$2.75Close, Nov 16
Market cap
$25.7M
Shares outstanding
9.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Adicet Bio, Inc.

All →
4:04 PM ET 8-K
Leadership Change

Adicet Bio Leadership Change

Dr. Andrew Sinclair resigned from the Board of Directors and its committees effective November 13, 2026, with the board size subsequently reduced from seven to six members. Following the resignation, current director Michael Grissinger was appointed to the Audit Committee and named chairperson of the Nominating and Corporate Governance Committee. The company stated the resignation was not due to any disagreements regarding operations, policies, or practices.

4:17 PM ET 8-K
Financial Results

Adicet Bio Financial Results

Adicet Bio reported third quarter 2026 financial results and provided updates on its clinical pipeline, including positive Phase 1 data for prula-cel in systemic lupus erythematosus. The company ended the quarter with $204.4 million in cash and cash equivalents, providing a projected runway into the second half of 2027.

Term
Q3 2026

“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients.”

Chen Schor, President and Chief Executive Officer of Adicet Bio
8:16 AM ET 8-K
Clinical Trial Data

Adicet Bio Clinical Trial Data

Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.

Earnings call
Sep 28, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.